作者
Mark D Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A Adas, Fabiola Atzeni, Kenrick KH Ng, Andrew I Rutherford, Sam Norton, Andrew P Cope, James B Galloway
发表日期
2023/8/1
期刊
Annals of the rheumatic diseases
卷号
82
期号
8
页码范围
1059-1067
出版商
BMJ Publishing Group Ltd
简介
Objectives
To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate.
Methods
Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) compared with placebo, TNFi or methotrexate, in adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy between JAKi and comparators. Bias was assessed using the Cochrane Risk of Bias-2 tool.
Results
In 62 eligible RCTs and 16 LTE studies, there were 82 366 person-years of exposure to JAKi …
学术搜索中的文章
MD Russell, C Stovin, E Alveyn, O Adeyemi, CKD Chan… - Annals of the rheumatic diseases, 2023